Research and Markets (http://www.researchandmarkets.com/research/sj7g24/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Wet (Neovascular / Exudative) Macular Degeneration Overview
  3. Therapeutics Development
  4. Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview
  5. Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis
  6. Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies
  7. Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes
  8. Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies
  13. Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes
  14. Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development

Companies Mentioned:

  • Aciont Inc.
  • Allergan Plc
  • Amakem NV
  • Apellis Pharmaceuticals, Inc.
  • Apexigen, Inc.
  • Applied Genetic Technologies Corporation
  • Avalanche Biotechnologies, Inc.
  • Benitec Biopharma Limited
  • BIOCAD
  • Boehringer Ingelheim GmbH
  • Charlesson LLC.
  • Chong Kun Dang Pharmaceutical Corp.
  • Circadian Technologies Limited
  • Clanotech AB
  • Clearside BioMedical, Inc.
  • Daiichi Sankyo Company, Limited
  • Eleven Biotherapeutics Inc.
  • Exonate Limited
  • F. Hoffmann-La Roche Ltd.
  • Formycon AG
  • GTx, Inc.
  • iCo Therapeutics Inc.
  • Icon Bioscience, Inc.
  • Kala Pharmaceuticals, Inc.
  • Mabion SA
  • Mitotech S.A.
  • Neurotech Pharmaceuticals, Inc.
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Ohr Pharmaceutical Inc.
  • Ophthotech Corp.
  • Oxford BioMedica Plc
  • PanOptica, Inc.
  • Pfenex Inc.
  • Pfizer Inc.
  • Quark Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • RegenxBio Inc.
  • RXi Pharmaceuticals Corporation
  • Santen Pharmaceutical Co., Ltd.
  • Sanwa Kagaku Kenkyusho Co., Ltd.
  • TRACON Pharmaceuticals, Inc.
  • TWi Pharmaceuticals, Inc.
  • Tyrogenex, Inc.
  • Xbrane Bioscience AB

For more information visit http://www.researchandmarkets.com/research/sj7g24/wet_neovascular